๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Chronic hepatitis C: Treatment of pegylated interferon/ ribavirin nonresponders

โœ Scribed by Mitchell L. Shiffman

Publisher
Current Science Inc.
Year
2006
Tongue
English
Weight
178 KB
Volume
5
Category
Article
ISSN
1540-3416

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Merimepodib, pegylated interferon, and r
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders
โœ Vinod K. Rustgi; William M. Lee; Eric Lawitz; Stuart C. Gordon; Nezam Afdhal; Fr ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 240 KB ๐Ÿ‘ 1 views

on behalf of the MErimepodib TRiple cOmbination (METRO) study group Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC) when combined with pegylated interferon alfa 2a (Peg-IFN-a